Astellas CEO Q&A (Part 1): There Is No Playbook on Cell and Gene Therapies
A Q&A with Naoki Okamura revealed that when it comes to cell and gene therapies, the CEO of Astellas Pharma believes risk-taking is a must for eventual success.
How Will Walgreens’ Expansion into Specialty Pharmacy Affect the Industry?
Walgreens announced that it is expanding its specialty pharmacy offerings. Experts think that this move could yield several strategic benefits, given the higher profit margins associated with specialty medications compared to traditional drugs. They also think Walgreens’ move could lead to greater competition, consolidation and innovation within the broader pharmacy industry.
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
Portfolio Management Strategies for Growth and Impact in Cell and Gene
As cell and gene therapies continue to make headlines as a key opportunity for growth, success in this field will require both innovative tech as well as strategic foresight.
Overcoming Barriers to Adherence in HIV: A Case for an Innovative Approach to Treatment
Innovation in the HIV treatment landscape is playing a role in addressing medication adherence. In recent years, long-acting injectable antiretroviral monthly and bi-monthly treatment options have been approved – a welcome alternative for people living with HIV. We are now on the cusp of it coming full circle from the days when patients took multiple pills a day to potentially a one-and-done single-dose treatment